News

Soligenix COVID-19 vaccine delivers broad immune response in pre-clinical testing

In a new study published on bioRxiv, Soligenix, Inc. reported that its CiVax COVID-19 vaccine demonstrated rapid, broad-spectrum, neutralizing antibody and immunity onset in preclinical studies.

The head stable vaccine used full-length Spike protein antigens to do its work, and at least in mice, it delivered. Primarily, the goal for this vaccine is to remove a major limitation on other, currently authorized vaccines: the need for refrigeration or freezing to transport and store them.

“We believe that creating a vaccine with enhanced stability at elevated temperatures that can obviate the costs and logistical burdens associated with cold chain storage, and distribution has the potential to simplify worldwide distribution, leading to a faster resolution of this pandemic and curtailing the further evolution of the virus,” Soligenix President and CEO Christopher Schaber said. “Once fully developed, we anticipate that our platform would be easily updated to address specific variants directly.”

Large animal studies and COVID variant testing are planned going forward, with that work aided by a $1.5 million small business innovation research (SBIR) grant awarded to Soligenix in December 2020. As part of this, Soligenix is collaborating with Dr. Axel Lehrer from the University of Hawai’i and determined the feasibility of developing a broadly immunogenic vaccine for COVID-19.

“Our work to date has demonstrated not only the feasibility of rapidly adaptable and cost-effective manufacturing of the required vaccine antigens but also the potential for a broadly applicable and easily distributed vaccine,” Lehrer said. “We are delighted with our earlier successes on development of filovirus and flavivirus vaccines with this platform.”

As part of its studies, Soligenix has licensed the CoVaccine HT adjuvant from BTG Specialty Pharmaceuticals. Work therein determined that CoVaccine HT can be thermostabilized both alone and in combination with antigens to produce a vaccine without col chain distribution or storage requirements.

Chris Galford

Recent Posts

Sen. Barrasso raises concerns over DOE’s ability to protect AI R&D from China

With artificial intelligence (AI) the increasing focus of interest for Washington and private companies, U.S.…

13 hours ago

Senate advances legislation that emphasizes federal building security

The Senate greenlit the Federal Building Security Act (S. 3613) this week, moving to the…

13 hours ago

Senate bill seeks to compel national security risk analysis of economic integration with China

A bipartisan group of senators recently introduced the American Economic Independence Act, which would require…

2 days ago

Sen. Peters presses federal agencies to increase cybersecurity for American health care

Citing cases where cyberattacks targeted health care systems in the United States, U.S. Sen. Gary…

2 days ago

U.S. Justice Department launches National Extreme Risk Protection Order Resource Center to curb gun violence

The U.S. Department of Justice recently launched a new resource center – the National Extreme…

3 days ago

Government funding agreement includes $3M allotment to create Northern Border security center

Among the provisions included in the recent $1.2 trillion funding agreement signed by President Joe…

3 days ago

This website uses cookies.